vs
百利高（PRGO）与SCANSOURCE, INC.（SCSC）财务数据对比。点击上方公司名可切换其他公司
百利高的季度营收约是SCANSOURCE, INC.的1.4倍（$1.1B vs $766.5M），SCANSOURCE, INC.净利率更高（2.2% vs -127.8%，领先130.0%），SCANSOURCE, INC.同比增速更快（2.5% vs -2.5%），百利高自由现金流更多（$148.6M vs $28.9M），过去两年百利高的营收复合增速更高（1.3% vs 0.9%）
百利高（Perrigo）是一家注册于爱尔兰的非处方仿制药生产商，主打自有品牌OTC药品业务。公司70%的净销售额来自美国医疗市场，为优化税务布局将法定总部设在爱尔兰，该地区销售额仅占总营收的0.6%，2013年曾完成美国历史上第六大企业税收倒置交易。
ScanSource是全球领先的专业技术分销商，主营销售点系统、条码扫描设备、网络安全产品、云服务及通信解决方案，面向北美、拉美、欧洲的增值经销商、服务提供商及企业客户，覆盖零售、医疗、工业、公共部门等领域。
PRGO vs SCSC — 直观对比
营收规模更大
PRGO
是对方的1.4倍
$766.5M
营收增速更快
SCSC
高出5.1%
-2.5%
净利率更高
SCSC
高出130.0%
-127.8%
自由现金流更多
PRGO
多$119.7M
$28.9M
两年增速更快
PRGO
近两年复合增速
0.9%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $766.5M |
| 净利润 | $-1.4B | $16.5M |
| 毛利率 | 32.6% | 13.4% |
| 营业利润率 | -116.0% | 2.3% |
| 净利率 | -127.8% | 2.2% |
| 营收同比 | -2.5% | 2.5% |
| 净利润同比 | -3093.9% | -3.3% |
| 每股收益（稀释后） | $-10.23 | $0.75 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PRGOSCSC
| Q4 25 | $1.1B | $766.5M | ||
| Q3 25 | $1.0B | $739.6M | ||
| Q2 25 | $1.1B | $812.9M | ||
| Q1 25 | $1.0B | $704.8M | ||
| Q4 24 | $1.1B | $747.5M | ||
| Q3 24 | $1.1B | $775.6M | ||
| Q2 24 | $1.1B | $746.1M | ||
| Q1 24 | $1.1B | $752.6M |
净利润PRGOSCSC
| Q4 25 | $-1.4B | $16.5M | ||
| Q3 25 | $7.5M | $19.9M | ||
| Q2 25 | $-8.4M | $20.1M | ||
| Q1 25 | $-6.4M | $17.4M | ||
| Q4 24 | $-44.4M | $17.1M | ||
| Q3 24 | $-21.0M | $17.0M | ||
| Q2 24 | $-108.4M | $16.1M | ||
| Q1 24 | $2.0M | $12.8M |
毛利率PRGOSCSC
| Q4 25 | 32.6% | 13.4% | ||
| Q3 25 | 36.1% | 14.5% | ||
| Q2 25 | 34.4% | 12.9% | ||
| Q1 25 | 37.6% | 14.2% | ||
| Q4 24 | 33.9% | 13.6% | ||
| Q3 24 | 37.2% | 13.1% | ||
| Q2 24 | 37.0% | 13.0% | ||
| Q1 24 | 33.1% | 12.6% |
营业利润率PRGOSCSC
| Q4 25 | -116.0% | 2.3% | ||
| Q3 25 | 7.0% | 3.5% | ||
| Q2 25 | 4.3% | 3.3% | ||
| Q1 25 | 4.5% | 3.2% | ||
| Q4 24 | 10.0% | 2.5% | ||
| Q3 24 | 7.4% | 2.3% | ||
| Q2 24 | -2.5% | 2.9% | ||
| Q1 24 | -5.1% | 2.3% |
净利率PRGOSCSC
| Q4 25 | -127.8% | 2.2% | ||
| Q3 25 | 0.7% | 2.7% | ||
| Q2 25 | -0.8% | 2.5% | ||
| Q1 25 | -0.6% | 2.5% | ||
| Q4 24 | -3.9% | 2.3% | ||
| Q3 24 | -1.9% | 2.2% | ||
| Q2 24 | -10.2% | 2.2% | ||
| Q1 24 | 0.2% | 1.7% |
每股收益（稀释后）PRGOSCSC
| Q4 25 | $-10.23 | $0.75 | ||
| Q3 25 | $0.05 | $0.89 | ||
| Q2 25 | $-0.06 | $0.87 | ||
| Q1 25 | $-0.05 | $0.74 | ||
| Q4 24 | $-0.32 | $0.70 | ||
| Q3 24 | $-0.15 | $0.69 | ||
| Q2 24 | $-0.79 | $0.66 | ||
| Q1 24 | $0.01 | $0.50 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $83.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.9B | $910.9M |
| 总资产 | $8.5B | $1.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PRGOSCSC
| Q4 25 | — | $83.5M | ||
| Q3 25 | $432.1M | $124.9M | ||
| Q2 25 | $454.2M | $126.2M | ||
| Q1 25 | $409.9M | $146.3M | ||
| Q4 24 | $558.8M | $110.5M | ||
| Q3 24 | $1.5B | $145.0M | ||
| Q2 24 | $542.8M | $185.5M | ||
| Q1 24 | $658.5M | $159.1M |
股东权益PRGOSCSC
| Q4 25 | $2.9B | $910.9M | ||
| Q3 25 | $4.4B | $914.0M | ||
| Q2 25 | $4.5B | $906.4M | ||
| Q1 25 | $4.4B | $901.7M | ||
| Q4 24 | $4.3B | $900.7M | ||
| Q3 24 | $4.6B | $920.9M | ||
| Q2 24 | $4.5B | $924.3M | ||
| Q1 24 | $4.7B | $944.1M |
总资产PRGOSCSC
| Q4 25 | $8.5B | $1.7B | ||
| Q3 25 | $10.1B | $1.7B | ||
| Q2 25 | $10.1B | $1.8B | ||
| Q1 25 | $9.8B | $1.7B | ||
| Q4 24 | $9.6B | $1.7B | ||
| Q3 24 | $11.2B | $1.8B | ||
| Q2 24 | $10.4B | $1.8B | ||
| Q1 24 | $10.6B | $1.8B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $175.4M | $30.8M |
| 自由现金流经营现金流 - 资本支出 | $148.6M | $28.9M |
| 自由现金流率自由现金流/营收 | 13.4% | 3.8% |
| 资本支出强度资本支出/营收 | 2.4% | 0.3% |
| 现金转化率经营现金流/净利润 | — | 1.87× |
| 过去12个月自由现金流最近4个季度 | $145.1M | — |
8季度趋势，按日历期对齐
经营现金流PRGOSCSC
| Q4 25 | $175.4M | $30.8M | ||
| Q3 25 | $51.7M | $23.2M | ||
| Q2 25 | $75.9M | — | ||
| Q1 25 | $-64.5M | $66.1M | ||
| Q4 24 | $312.6M | $-6.2M | ||
| Q3 24 | $42.2M | $44.8M | ||
| Q2 24 | $9.5M | — | ||
| Q1 24 | $-1.4M | $160.2M |
自由现金流PRGOSCSC
| Q4 25 | $148.6M | $28.9M | ||
| Q3 25 | $29.8M | $20.8M | ||
| Q2 25 | $56.7M | — | ||
| Q1 25 | $-90.0M | $64.6M | ||
| Q4 24 | $274.9M | $-8.2M | ||
| Q3 24 | $15.1M | $42.5M | ||
| Q2 24 | $-18.9M | — | ||
| Q1 24 | $-26.5M | $157.7M |
自由现金流率PRGOSCSC
| Q4 25 | 13.4% | 3.8% | ||
| Q3 25 | 2.9% | 2.8% | ||
| Q2 25 | 5.4% | — | ||
| Q1 25 | -8.6% | 9.2% | ||
| Q4 24 | 24.2% | -1.1% | ||
| Q3 24 | 1.4% | 5.5% | ||
| Q2 24 | -1.8% | — | ||
| Q1 24 | -2.4% | 21.0% |
资本支出强度PRGOSCSC
| Q4 25 | 2.4% | 0.3% | ||
| Q3 25 | 2.1% | 0.3% | ||
| Q2 25 | 1.8% | 0.3% | ||
| Q1 25 | 2.4% | 0.2% | ||
| Q4 24 | 3.3% | 0.3% | ||
| Q3 24 | 2.5% | 0.3% | ||
| Q2 24 | 2.7% | 0.2% | ||
| Q1 24 | 2.3% | 0.3% |
现金转化率PRGOSCSC
| Q4 25 | — | 1.87× | ||
| Q3 25 | 6.89× | 1.17× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 3.79× | ||
| Q4 24 | — | -0.36× | ||
| Q3 24 | — | 2.64× | ||
| Q2 24 | — | — | ||
| Q1 24 | -0.70× | 12.51× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
SCSC
| Products And Services | $723.4M | 94% |
| Intelisys Advisory | $25.0M | 3% |
| Recurring Revenue | $18.2M | 2% |
